혈액가스 및 전해질 분석기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Blood Gas And Electrolyte Analyzer Market Growth & Trends:

The global blood gas and electrolyte analyzer market size is expected to reach USD 3.71 billion by 2030, registering a CAGR of 4.5%, according to a new study by Grand View Research Inc. Rising number of patients in ICU and critical care units and increasing demand for high throughput and integrated systems are some key factors likely to drive the blood gas and electrolyte analyzers market. Growing global geriatric population base is also expected to significantly contribute towards market growth over the forecast period, by triggering the incidence rates of target diseases and widening the base of patients requiring critical care. Furthermore, the emergence of multi-parameter monitoring devices owing to, expanding test menus and growing demand for portable devices is expected to boost usage rates over the forecast period. The availability of blood gas analyzers has helped enhance the care of critically ill patients allowing for frequent diagnosis and monitoring of respiratory problems and ability to guide prognosis and therapy. Rising demand for technically advanced sleek handheld devices involving short turnaround time has resulted in the development of more compact, sleek, handheld point-of-care devices. For instance, the OPTI CCA-TS2 blood gas and electrolyte analyzers use innovative optical technology and provide fast results while requiring minimal maintenance.

Blood Gas And Electrolyte Analyzer Market Report Highlights:

• Consumables dominated the market with a revenue share of 66.28% in 2023 and is anticipated to grow at the fastest growth rate over the forecast period, driven by their increasing demand.
• Clinical laboratory dominated the market with a revenue market share of 46.98% in 2023. In the rapidly advancing landscape of healthcare technology, Blood Gas Analyzers (BGAs) have become indispensable for clinical laboratories, offering real-time insights into a patient's respiratory and metabolic status.
• North America accounted for 42.22% of the blood gas and electrolyte analyzers market in 2023. Presence of sophisticated healthcare infrastructure along with favorable reimbursement plans are some key factors expected to drive regional market growth.
• Presence of high unmet needs clubbed with rapidly improving healthcare infrastructure in the emerging markets of India and China is expected to help Asia Pacific grow at a lucrative rate throughout the forecast period. Growing demand for decentralized point-of-care diagnostic facilities handling large volumes of diagnostic tests is also expected to drive regional market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and end-use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Gas and Electrolyte Analyzer Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing prevalence of chronic diseases
    • 3.2.1.2. Rising geriatric population
    • 3.2.1.3. Increasing regulatory support and funding
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced analyzers
    • 3.2.2.2. Shortage of skilled professionals
• 3.3. Blood Gas and Electrolyte Analyzer Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Blood Gas and Electrolyte Analyzer Market: Product Estimates & Trend Analysis

• 4.1. Global Blood Gas and Electrolyte Analyzer Market: Product Dashboard
• 4.2. Global Blood Gas and Electrolyte Analyzer Market: Product Movement Analysis
• 4.3. Global Blood Gas and Electrolyte Analyzer Market by Product, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Instruments, by Type
  • 4.4.3. Bench Top
    • 4.4.3.1. Benchtop instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. Portable
    • 4.4.4.1. Portable instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.5. Instruments, by Brand
  • 4.4.6. I-STAT
    • 4.4.6.1. I-STAT market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.7. epoc
    • 4.4.7.1. epoc market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.8. GEM Premier (3500& 5000)
    • 4.4.8.1. GEM Premier (3500& 5000) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.9. ABL Flex (90 and 800)
    • 4.4.9.1. ABL Flex (90 and 800) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.10. Cobas
    • 4.4.10.1. Cobas market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.11. Portable RAPID Series
    • 4.4.11.1. RAPID series market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.12. Others
    • 4.4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Blood Gas and Electrolyte Analyzer Market: End Use Estimates & Trend Analysis

• 5.1. Global Blood Gas and Electrolyte Analyzer Market: End Use Dashboard
• 5.2. Global Blood Gas and Electrolyte Analyzer Market: End Use Movement Analysis
• 5.3. Global Blood Gas and Electrolyte Analyzer Market by End Use, Revenue
• 5.4. Clinical Laboratory
  • 5.4.1. Clinical laboratory market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Point-of-care
  • 5.5.1. Point-of-care market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Diagnostic Centers
  • 5.6.1. Diagnostic centers market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Blood Gas and Electrolyte Analyzer Market: Regional Estimates & Trend Analysis by Product and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.7. Malaysia
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.8. Indonesia
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.9. Thailand
    • 6.5.9.1. Key country dynamics
    • 6.5.9.2. Regulatory framework/ reimbursement structure
    • 6.5.9.3. Competitive scenario
    • 6.5.9.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.10. Vietnam
    • 6.5.10.1. Key country dynamics
    • 6.5.10.2. Regulatory framework/ reimbursement structure
    • 6.5.10.3. Competitive scenario
    • 6.5.10.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.11. Philippines
    • 6.5.11.1. Key country dynamics
    • 6.5.11.2. Regulatory framework/ reimbursement structure
    • 6.5.11.3. Competitive scenario
    • 6.5.11.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Abbott
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Meizhou Cornley High-Tech Co., Ltd.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Radiometer Medical ApS
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. EDAN Instruments, Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Erba Mannheim
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. F. Hoffmann-La Roche Ltd
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Fortress Diagnostics
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Werfen
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. LifeHealth
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Medica Corporation
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. OPTI Medical Systems, Inc.,
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Sensa Core
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Siemens Healthineers AG
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives